abcam

ab108623

Anti-Galectin 7 antibody [EPR4287]

Recombinant RabMAb

Key facts

Isotype	IgG
Host species	Rabbit
Storage buffer	pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Form	Liquid
Clonality	Monoclonal
Immunogen	The exact immunogen used to generate this antibody is proprietary information.
Clone number	EPR4287
Purification technique	Affinity purification Protein A
Concentration	0.527 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →

Reactivity data

IHC-P

Tested

Species	Human
Dilution info	1/1500
Notes	-

ICC/IF

Tested

Species	Human
Dilution info	1/1000
Notes	-

IP

Tested

Species	Human
Dilution info	1/10 - 1/100
Notes	-

WB

Tested

Species	Human
Dilution info	1/1000 - 1/10000
Notes	-

Flow Cyt (Intra)

Tested

Species	Human
Dilution info	1/50
Notes	-

Target data

See full target information LGALS7

Function	Could be involved in cell-cell and/or cell-matrix interactions necessary for normal growth control. Pro-apoptotic protein that functions intracellularly upstream of JNK activation and cytochrome c release.

Storage

Shipped at conditions	Conditional Ambient
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	-20°C
Storage information	Stable for 12 months at -20°C

Notes

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary	Galectin 7 also known as Gal-7 is a member of the galectin family of beta-galactoside-binding proteins. It has a molecular mass of approximately 15 kDa. Structurally Galectin 7 has a single carbohydrate recognition domain (CRD) which allows it to bind glycoconjugates. Galectin 7 expresses in various tissues with high expression levels in the epidermis and in stratified squamous epithelia.
Biological function summary	Galectin 7 plays a role in cell-cell adhesion apoptosis regulation and immune response modulation. It plays a role in the cell's apoptosis machinery and interacts with the cytochrome c release pathway. This protein does not typically form a part of large complexes functioning individually in most biological processes. It can influence keratinocyte migration indicating involvement in wound healing processes.

Pathways	Galectin 7 participates in the apoptosis and cell adhesion pathways. It works alongside proteins such as Bcl-2 and Bax to regulate programmed cell death by promoting apoptosis. Additionally it interacts with matrix metalloproteinases influencing the remodelling of extracellular matrix a critical component of tissue repair and immune response.
Associated diseases and disorders	Galectin 7 is associated with cancer and psoriasis. In cancer it can act as a pro-apoptotic factor and modulates tumor progression often in concert with p53 a well-known tumor suppressor protein. In psoriasis aberrant expression of Galectin 7 correlates with impaired epidermal function and inflammation suggesting it may alter the disease course by influencing local immune responses and keratinocyte behavior.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended


We do not recommend this combination. It is not covered by our product promise.

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.


5 product images



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Galectin 7 antibody [EPR4287] (ab108623)

Galectin 7 Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) staining using rabbit Anti-Galectin 7 antibody


Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human tonsil tissue sections labeling Galectin 7 with purified ab108623 at 1/1500 dilution (0.35 µg/mL). Heat mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0). The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.



Flow Cytometry (Intracellular) - Anti-Galectin 7 antibody [EPR4287] (ab108623)

Galectin 7 Flow Cytometry (Intracellular) staining using rabbit Anti-Galectin 7 antibody


Intracellular Flow Cytometry analysis of HaCaT (Human skin keratinocyte) cells labeling Galectin 7 with Purified ab108623 at 1/50 dilution (10 µg/ml) (Red). Cells were fixed with 4% Paraformaldehyde and permeabilised with 90% Methanol. A Goat anti rabbit IgG (Alexa Fluor® 488 ,ab150077) secondary antibody was used at 1/2000. Isotype control - Rabbit monoclonal IgG (Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).



Immunocytochemistry/ Immunofluorescence - Anti-Galectin 7 antibody [EPR4287] (ab108623)

Galectin 7 Immunocytochemistry/ Immunofluorescence staining using rabbit Anti-Galectin 7 antibody

Immunocytochemistry analysis of HaCaT (Human skin keratinocyte) cells labeling Galectin 7 with Purified ab108623 at 1:1000 dilution (0.5 µg/ml). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1:200 (2.5 µg/ml). Goat anti rabbit IgG (Alexa Fluor® 488,ab150077) was used as the secondary antibody at 1:1000 (2 µg/ml) dilution. DAPI (blue) was used as nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.



Immunoprecipitation - Anti-Galectin 7 antibody [EPR4287] (ab108623)

Purified ab108623 at 1/50 dilution (2µg) immunoprecipitating Galectin 7 in HaCaT whole cell lysate.
Lane 1 (input): HaCaT (Human skin keratinocyte) whole cell lysate 10µg
Lane 2 (+): ab108623 + HaCaT whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab108623 in HaCaT whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/1000 dilution) was used for Western blotting.
Blocking Buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Observed band size: 15 kDa
All lanes:

Immunoprecipitation - Anti-Galectin 7 antibody [EPR4287] (ab108623)

Predicted band size: 15 kDa



Western blot - Anti-Galectin 7 antibody [EPR4287] (ab108623)

All lanes:
Western blot - Anti-Galectin 7 antibody [EPR4287] (ab108623) at 1/1000 dilution

All lanes:
Human skin lysate

Secondary

All lanes:
Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

Predicted band size: 15 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.